Works by Blank, C. U.

Results: 14
    1
    2

    Adjuvant BRAF/MEK versus anti-PD-1 in BRAF-mutant melanoma: a propensity score matched survival analysis.

    Published in:
    British Journal of Cancer, 2025, v. 132, n. 12, p. 1124, doi. 10.1038/s41416-025-03021-5
    By:
    • Bloem, M.;
    • de Meza, M. M.;
    • van den Eertwegh, A. J. M.;
    • Aarts, M. J. B.;
    • van den Berkmortel, F. W. P. J.;
    • Blank, C. U.;
    • Blokx, W. A. M.;
    • Boers-Sonderen, M. J.;
    • Bonenkamp, J. J.;
    • Boreel, C. D. M.;
    • de Groot, J. W. B.;
    • Haanen, J. B. A. G.;
    • Hospers, G. A. P.;
    • Kapiteijn, E.;
    • van Not, O. J.;
    • Piersma, D.;
    • Rikhof, B.;
    • Stevense-den Boer, A. M.;
    • van der Veldt, A. A. M.;
    • Vreugdenhil, G.
    Publication type:
    Article
    3
    4

    Immune checkpoint inhibitor-induced neurotoxicity is not associated with seroprevalence of neurotropic infections.

    Published in:
    Cancer Immunology, Immunotherapy, 2023, v. 72, n. 11, p. 3475, doi. 10.1007/s00262-023-03498-0
    By:
    • Schmitt, C.;
    • Hoefsmit, E. P.;
    • Fangmeier, T.;
    • Kramer, N.;
    • Kabakci, C.;
    • Vera González, J.;
    • Versluis, J. M.;
    • Compter, A.;
    • Harrer, T.;
    • Mijočević, H.;
    • Schubert, S.;
    • Hundsberger, T.;
    • Menzies, A. M.;
    • Scolyer, R. A.;
    • Long, G. V.;
    • French, L. E.;
    • Blank, C. U.;
    • Heinzerling, L. M.
    Publication type:
    Article
    5

    Health-related quality of life of long-term advanced melanoma survivors treated with anti-CTLA-4 immune checkpoint inhibition compared to matched controls.

    Published in:
    Acta Oncologica, 2021, v. 60, n. 1, p. 69, doi. 10.1080/0284186X.2020.1818823
    By:
    • Boekhout, A. H.;
    • Rogiers, A.;
    • Jozwiak, K.;
    • Boers-Sonderen, M. J.;
    • van den Eertwegh, A. J.;
    • Hospers, G. A.;
    • de Groot, J. W. B.;
    • Aarts, M. J. B.;
    • Kapiteijn, E.;
    • ten Tije, A. J.;
    • Piersma, D.;
    • Vreugdenhil, G.;
    • van der Veldt, A. A.;
    • Suijkerbuijk, K. P. M.;
    • Rozeman, E. A.;
    • Neyns, B.;
    • Janssen, K. J.;
    • van de Poll-Franse, L. V.;
    • Blank, C. U.
    Publication type:
    Article
    6
    7

    Conversion of unresponsiveness to immune checkpoint inhibition by fecal microbiota transplantation in patients with metastatic melanoma: study protocol for a randomized phase Ib/IIa trial.

    Published in:
    BMC Cancer, 2022, v. 22, n. 1, p. 1, doi. 10.1186/s12885-022-10457-y
    By:
    • Borgers, J. S. W.;
    • Burgers, F. H.;
    • Terveer, E. M.;
    • van Leerdam, M. E.;
    • Korse, C. M.;
    • Kessels, R.;
    • Flohil, C. C.;
    • Blank, C. U.;
    • Schumacher, T. N.;
    • van Dijk, M.;
    • Henderickx, J. G. E.;
    • Keller, J. J.;
    • Verspaget, H. W.;
    • Kuijper, E. J.;
    • Haanen, J. B. A. G.
    Publication type:
    Article
    8
    9

    Combining Melphalan Percutaneous Hepatic Perfusion with Ipilimumab Plus Nivolumab in Advanced Uveal Melanoma: First Safety and Efficacy Data from the Phase Ib Part of the Chopin Trial.

    Published in:
    CardioVascular & Interventional Radiology, 2023, v. 46, n. 3, p. 350, doi. 10.1007/s00270-022-03338-1
    By:
    • Tong, T. M. L.;
    • Burgmans, M. C.;
    • Speetjens, F. M.;
    • van Erkel, A. R.;
    • van der Meer, R. W.;
    • van Rijswijk, C. S. P.;
    • Jonker-Bos, M. A.;
    • Roozen, C. F. M.;
    • Sporrel-Blokland, M.;
    • Lutjeboer, J.;
    • van Persijn van Meerten, E. L.;
    • Martini, C. H.;
    • Zoethout, R. W. M.;
    • Tijl, F. G. J.;
    • Blank, C. U.;
    • Kapiteijn, E.
    Publication type:
    Article
    10

    Safe Stop IPI-NIVO trial: early discontinuation of nivolumab upon achieving a complete or partial response in patients with irresectable stage III or metastatic melanoma treated with first-line ipilimumab-nivolumab – study protocol.

    Published in:
    BMC Cancer, 2024, v. 24, n. 1, p. 1, doi. 10.1186/s12885-024-12336-0
    By:
    • Janssen, J. C.;
    • van Dijk, B.;
    • de Joode, K.;
    • Aarts, M. J. B.;
    • van den Berkmortel, F. W. P. J.;
    • Blank, C. U.;
    • Boers-Sonderen, M. J.;
    • van den Eertwegh, A. J. M.;
    • de Groot, J. W. B.;
    • Jalving, M.;
    • de Jonge, M. J. A.;
    • Joosse, A.;
    • Kapiteijn, E.;
    • Kamphuis-Huismans, A. M.;
    • Naipal, K. A. T.;
    • Piersma, D.;
    • Rikhof, B.;
    • Westgeest, H. M.;
    • Vreugdenhil, G.;
    • Oomen-de Hoop, E.
    Publication type:
    Article
    11

    Seasonal variation of anti‐PD‐1 outcome in melanoma—Results from a Dutch patient cohort.

    Published in:
    Pigment Cell & Melanoma Research, 2024, v. 37, n. 1, p. 15, doi. 10.1111/pcmr.13117
    By:
    • Borgers, J. S. W.;
    • Burgers, F. H.;
    • Schina, A.;
    • Van Not, O. J.;
    • van den Eertwegh, A. J. M.;
    • Blank, C. U.;
    • Aarts, M. J. B.;
    • van den Berkmortel, F. W. P. J.;
    • de Groot, J. W. B.;
    • Hospers, G. A. P.;
    • Kapiteijn, E.;
    • Piersma, D.;
    • van Rijn, R. S.;
    • Boer, A. M. Stevense‐den;
    • van der Veldt, A. A. M.;
    • Vreugdenhil, G.;
    • Boers‐Sonderen, M. J.;
    • Wouters, M. W. J. M.;
    • Suijkerbuijk, K. P. M.;
    • van Thienen, J. V.
    Publication type:
    Article
    12

    Health-state utilities in long-term advanced melanoma survivors comparable with the general population.

    Published in:
    Quality of Life Research, 2023, v. 32, n. 9, p. 2517, doi. 10.1007/s11136-023-03427-9
    By:
    • Egeler, M. D.;
    • van de Poll-Franse, L. V.;
    • Tissier, R.;
    • Rogiers, A.;
    • Boers-Sonderen, M. J.;
    • van den Eertwegh, A. J.;
    • Hospers, G. A.;
    • de Groot, J. W. B.;
    • Aarts, M. J. B.;
    • Kapiteijn, E.;
    • Piersma, D.;
    • Vreugdenhil, G.;
    • van der Veldt, A. A.;
    • Suijkerbuijk, K. P. M.;
    • Neyns, B.;
    • Janssen, K. J.;
    • Blank, C. U.;
    • Retèl, V. P.;
    • Boekhout, A. H.
    Publication type:
    Article
    13
    14